---
type: "Symbol"
title: "Newamsterdam Pharma (NAMS.US) — 社區討論"
description: "該股票的社區討論，包括分析師觀點、財報解讀和投資策略，來自認證金融專業人士和活躍投資者。"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/NAMS.US/topics.md"
symbol: "NAMS.US"
parent: "https://longbridge.com/zh-HK/quote/NAMS.US.md"
count: 1
datetime: "2026-03-14T18:50:17.409Z"
locales:
  - [en](https://longbridge.com/en/quote/NAMS.US/topics.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NAMS.US/topics.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NAMS.US/topics.md)
---

# Newamsterdam Pharma (NAMS.US) — 社區討論

### [The Lancet: Phase III clinical trial shows obicetrapib combined with ezetimibe is safe and effective in lowering cholesterol.](https://longbridge.com/zh-HK/topics/29596329.md)

- 作者: [济无咎](https://longbridge.com/zh-HK/profiles/9874868.md)
- 日期時間: 2025-05-13T16:04:56.000Z
- 評論: 0
- Obicetrapib is jointly developed by multiple companies, including $Amgen(AMGN.US) and Mitsubishi Tanabe Pharma, and is currently mainly developed and researched by $Newamsterdam Pharma(NAMS.US). Ezeti

## 參考連結

- [Newamsterdam Pharma (NAMS.US)](https://longbridge.com/zh-HK/quote/NAMS.US.md)


> 支持的語言: [English](https://longbridge.com/en/quote/NAMS.US/topics.md) | [简体中文](https://longbridge.com/zh-CN/quote/NAMS.US/topics.md)